Global Insulin Delivery Devices Market Research and Forecast 2017-2022
The Global Insulin Delivery Devices Market is expected to grow at the CAGR of 8.5% during 2017-2022. There are various pivotal factors that are boosting the market growth which includes rising incidence and prevalence rate of diabetes patients, increasing awareness among population towards the diabetes and a variety of insulin delivery devices and so forth. Insulin is a necessary element required for the treatment diabetes patients. Insulin enables a person’s body to use glucose from carbohydrates in the food consumed by the patient for future use. Insulin delivery is an approach used for delivering the insulin to a patient’s body through their fatty tissues. Rising diabetes patients are considered to be a key driver in the growth of global insulin delivery devices market. According to WHO, the number of people with diabetes has increased from 108 million in 1980 to 422 million in 2014. While, in 2015, approx 1.6 million deaths were reported due to diabetes. This significant increase in diabetes population and its effects have boosted the insulin delivery devices market significantly. Additionally, the government support and their reimbursement policies in some countries such as U.S are driving the market growth in a positive way. Federal government offers financial support to diabetes patients by providing them various health insurances. Medicare, the Children’s Health Insurance Program (CHIP), TRICARE, and veterans’ health care programs are some programs which supports patients. Moreover, some acts such as Affordable Care Act (ACA) prevents insurers from denying coverage or charging higher premiums to people with preexisting conditions, such as diabetes are also boosting the market considerably. The features of insulin delivery devices including its accuracy, efficiency and cost-effectiveness attract the customers from different regions and thus drive the market growth.
There is a lack of reimbursement policies in some emerging economies such as Bulgaria; Czech Republic and so on which does not give so much priority to diabetes. In addition to policies, risk of infections associated with some devices such as insulin pens and syringes acts as a restraint for the market. The adoption of oral insulin as an alternative to these devices is negatively impacting the market. However, technological advancement and innovations to prevent this contamination and the significant rise in the amount of spending on diabetes are expected to create opportunities in the future.
Geographical Insights
Cohesive government policies and the high adoption of insulin delivery devices make North America a dominant region in the insulin delivery devices market. Additionally, high prevalence of diabetes and high diagnosis rate are some other factors that are driving the market North American market. APAC region is expected to be the fast growing region due to the more number of diabetes patients in the Asian countries such as China, India, Japan and so on. Moreover, rising awareness in APAC regions about diabetes and treatment are expected to boost the insulin delivery market.
Competitive Insights
The key players which serve a major part of the diabetic population are Abbott Laboratories, Animas Corporation, Becton, Dickinson and Company, Biocon, ELI Lilly and Company, F. Hoffmann-La Roche, Ltd., Mannkind Corporation, Medtronic PLC Novo Nordisk A/S, Tandem Diabetes Care, Inc., Sanofi and SciGen and so on. Insulin Delivery Devices market companies are constantly focusing on product launch, R&D, partnerships, M&A, innovation and technological advancement. One such strategic partnership was done by Sanofi and AgaMatrix which both develop cutting-edge solutions in diabetes management. The report also includes detailed market overview, strategic recommendations, key company analysis, key findings, analyst insights, predictive analysis, pipeline analysis, market determinants, market segmentation, geographical analysis, company profiling of the market.
Market Segmentation
Global Insulin Delivery Devices Market can be bifurcated on the basis of device type, its distribution channel and its usage in end industries. The Reusable Insulin Pens are the most widely used device in the market. While, on the basis of end-users industry, the homecare applications holds the largest share of the market. Global Insulin Delivery Devices Market is segmented on the basis of three major categories which includes –
Global Insulin Delivery Devices Market Research and Analysis, By Type
Global Insulin Delivery Devices Market Research and Analysis, By Distribution Channel
Global Insulin Delivery Devices Market Research and Analysis, By End-User Industry
The report covers
There is a lack of reimbursement policies in some emerging economies such as Bulgaria; Czech Republic and so on which does not give so much priority to diabetes. In addition to policies, risk of infections associated with some devices such as insulin pens and syringes acts as a restraint for the market. The adoption of oral insulin as an alternative to these devices is negatively impacting the market. However, technological advancement and innovations to prevent this contamination and the significant rise in the amount of spending on diabetes are expected to create opportunities in the future.
Geographical Insights
Cohesive government policies and the high adoption of insulin delivery devices make North America a dominant region in the insulin delivery devices market. Additionally, high prevalence of diabetes and high diagnosis rate are some other factors that are driving the market North American market. APAC region is expected to be the fast growing region due to the more number of diabetes patients in the Asian countries such as China, India, Japan and so on. Moreover, rising awareness in APAC regions about diabetes and treatment are expected to boost the insulin delivery market.
Competitive Insights
The key players which serve a major part of the diabetic population are Abbott Laboratories, Animas Corporation, Becton, Dickinson and Company, Biocon, ELI Lilly and Company, F. Hoffmann-La Roche, Ltd., Mannkind Corporation, Medtronic PLC Novo Nordisk A/S, Tandem Diabetes Care, Inc., Sanofi and SciGen and so on. Insulin Delivery Devices market companies are constantly focusing on product launch, R&D, partnerships, M&A, innovation and technological advancement. One such strategic partnership was done by Sanofi and AgaMatrix which both develop cutting-edge solutions in diabetes management. The report also includes detailed market overview, strategic recommendations, key company analysis, key findings, analyst insights, predictive analysis, pipeline analysis, market determinants, market segmentation, geographical analysis, company profiling of the market.
Market Segmentation
Global Insulin Delivery Devices Market can be bifurcated on the basis of device type, its distribution channel and its usage in end industries. The Reusable Insulin Pens are the most widely used device in the market. While, on the basis of end-users industry, the homecare applications holds the largest share of the market. Global Insulin Delivery Devices Market is segmented on the basis of three major categories which includes –
Global Insulin Delivery Devices Market Research and Analysis, By Type
Global Insulin Delivery Devices Market Research and Analysis, By Distribution Channel
Global Insulin Delivery Devices Market Research and Analysis, By End-User Industry
The report covers
- Comprehensive research methodology of Global Insulin Delivery Devices Market.
- This report also includes detailed and extensive market overview with current market recommendations & key analysts insights.
- Exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
- Analysis of regional regulations and other government policies impacting the Global Insulin Delivery Devices Market.
- Insights about market determinants which are stimulating the Global Insulin Delivery Devices Market.
- Detailed and extensive market segments with regional distribution of forecasted revenues.
- Extensive profiles and recent developments of market players.
REPORT SUMMARY
1.1. RESEARCH METHODS AND TOOLS
1.2. MARKET BREAKDOWN
1.2.1. BY SEGMENTS
1.2.2. BY GEOGRAPHY
1.2.3. BY STAKEHOLDERS
MARKET OVERVIEW AND INSIGHTS
2.1. DEFINITION
2.2. ANALYST INSIGHT & CURRENT MARKET TRENDS
2.2.1. KEY FINDINGS
2.2.2. RECOMMENDATION
2.2.3. CONCLUSION
2.3. REGULATIONS
2.3.1. UNITED STATES
2.3.2. EUROPEAN UNION
2.3.3. CHINA
2.3.4. INDIA
2.3.5. REST OF THE WORLD
2.4. PATENT ANALYSIS
MARKET DETERMINANT
3.1. MOTIVATORS
3.1.1. RISE IN PREVALENCE RATE OF DIABETES
3.1.2. INCREASE IN AWARENESS TOWARDS DIABETES AND INSULIN DELIVERY DEVICES
3.1.3. GOVERNMENT SUPPORT AND FAVOURABLE REIMBURSEMENT IN SOME ECONOMIES
3.1.4. ACCURACY AND EFFICIENCY OF INSULIN DELIVERY DEVICES
3.2. RESTRAINTS
3.2.1. RISK OF INFECTION WITH NEEDLES AND SYRINGES
3.2.2. LACK OF REIMBURSEMENT POLICIES IN SOME COUNTRIES
3.2.3. ORAL INSULIN EMERGING AS AN ALTERNATIVE OPTION
3.3. OPPORTUNITIES
3.3.1. TECHNOLOGICAL ADVANCEMENTS
3.3.2. GROWTH OF RESEARCH AND DELIVERY ACTIVITIES
3.3.3. INCREASE IN DIABETES RELATED SPENDING IN EMERGING ECONOMIES
MARKET SEGMENTATION
4.1. INSULIN DELIVERY DEVICES MARKET BY TYPE
4.1.1. INSULIN SYRINGES
4.1.2. INSULIN PENS
4.1.3. INSULIN JET INJECTORS
4.1.4. EXTERNAL INSULIN PUMPS
4.1.5. OTHERS
4.2. INSULIN DELIVERY DEVICES MARKET BY DISTRIBUTION CHANNELS
4.2.1. HOSPITALS PHARMACY
4.2.2. ONLINE SALES
4.2.3. DIABETES CENTRES
4.2.4. RETAIL PHARMACY
4.3. INSULIN DELIVERY DEVICES MARKET BY END-USER INDUSTRY
4.3.1. HOSPITALS & CLINICS
4.3.2. HOMECARE USAGE
COMPETITIVE LANDSCAPE
5.1. KEY STRATEGIES
5.2. KEY COMPANY ANALYSIS
REGIONAL ANALYSIS
6.1. NORTH AMERICA
6.1.1. UNITED STATES
6.1.2. CANADA
6.1.3. REST OF NORTH AMERICA
6.2. EUROPE
6.2.1. UNITED KINGDOM
6.2.2. FRANCE
6.2.3. GERMANY
6.2.4. ITALY
6.2.5. SPAIN
6.2.6. REST OF EUROPE
6.3. ASIA PACIFIC
6.3.1. INDIA
6.3.2. CHINA
6.3.3. JAPAN
6.4. REST OF THE WORLD
COMPANY PROFILES
7.1. ABBOTT LABORATORIES
7.1.1. INTRODUCTION
7.1.2. ABBOTT LABORATORIES PRODUCT PORTFOLIO
7.1.3. ABBOTT LABORATORIES RECENT ACTIVITIES
7.2. ANIMAS CORPORATION
7.2.1. INTRODUCTION
7.2.2. ANIMAS CORPORATION PRODUCT PORTFOLIO
7.2.3. ANIMAS CORPORATION RECENT ACTIVITIES
7.3. ASTRAZENECA PLC
7.3.1. INTRODUCTION
7.3.2. ASTRAZENECA PLC PRODUCT PORTFOLIO
7.3.3. ASTRAZENECA PLC RECENT ACTIVITIES
7.4. B. BRAUN MESELGEN AG
7.4.1. INTRODUCTION
7.4.2. B. BRAUN MESELGEN AG PRODUCT PORTFOLIO
7.4.3. B. BRAUN MESELGEN AG RECENT ACTIVITIES
7.5. BECTON, DICKINSON AND COMPANY
7.5.1. INTRODUCTION
7.5.2. BECTON, DICKINSON AND COMPANY PRODUCT PORTFOLIO
7.5.3. BECTON, DICKINSON AND COMPANY RECENT ACTIVITIES
7.6. BIOCON LIMITED
7.6.1. INTRODUCTION
7.6.2. BIOCON LIMITED PRODUCT PORTFOLIO
7.6.3. BIOCON LIMITED RECENT ACTIVITIES
7.7. BRISTOL-MYERS SQUIBB
7.7.1. INTRODUCTION
7.7.2. BRISTOL-MYERS SQUIBB PRODUCT PORTFOLIO
7.7.3. BRISTOL-MYERS SQUIBB RECENT ACTIVITIES
7.8. ELI LILLY AND COMPANY
7.8.1. INTRODUCTION
7.8.2. ELI LILLY AND COMPANY PRODUCT PORTFOLIO
7.8.3. ELI LILLY AND COMPANY RECENT ACTIVITIES
7.9. F. HOFFMANN-LA ROCHE, LTD.
7.9.1. INTRODUCTION
7.9.2. F. HOFFMANN-LA ROCHE, LTD. PRODUCT PORTFOLIO
7.9.3. F. HOFFMANN-LA ROCHE, LTD. RECENT ACTIVITIES
7.10. INSULET CORPORATION
7.10.1. INTRODUCTION
7.10.2. INSULET CORPORATION PRODUCT PORTFOLIO
7.10.3. INSULET CORPORATION RECENT ACTIVITIES
7.11. JULPHAR
7.11.1. INTRODUCTION
7.11.2. JULPHAR PRODUCT PORTFOLIO
7.11.3. JULPHAR RECENT ACTIVITIES
7.12. MANNKIND CORPORATION
7.12.1. INTRODUCTION
7.12.2. MANNKIND CORPORATION PRODUCT PORTFOLIO
7.12.3. MANNKIND CORPORATION RECENT ACTIVITIES
7.13. MEDTRONIC PLC
7.13.1. INTRODUCTION
7.13.2. MEDTRONIC PLC PRODUCT PORTFOLIO
7.13.3. MEDTRONIC PLC RECENT ACTIVITIES
7.14. NOVO NORDISK A/S
7.14.1. INTRODUCTION
7.14.2. NOVO NORDISK A/S PRODUCT PORTFOLIO
7.14.3. NOVO NORDISK A/S RECENT ACTIVITIES
7.15. PFIZER INC.
7.15.1. INTRODUCTION
7.15.2. PFIZER INC. PRODUCT PORTFOLIO
7.15.3. PFIZER INC. A/S RECENT ACTIVITIES
7.16. SANOFI
7.16.1. INTRODUCTION
7.16.2. SANOFI PRODUCT PORTFOLIO
7.16.3. SANOFI RECENT ACTIVITIES
7.17. SCIGEN
7.17.1. INTRODUCTION
7.17.2. SCIGEN PRODUCT PORTFOLIO
7.17.3. SCIGEN RECENT ACTIVITIES
7.18. TANDEM DIABETES CARE, INC.
7.18.1. INTRODUCTION
7.18.2. TANDEM DIABETES CARE, INC. PRODUCT PORTFOLIO
7.18.3. TANDEM DIABETES CARE, INC. RECENT ACTIVITIES
7.19. WOCKHARDT LTD.
7.19.1. INTRODUCTION
7.19.2. WOCKHARDT LTD. PRODUCT PORTFOLIO
7.19.3. WOCKHARDT LTD. RECENT ACTIVITIES
7.20. YPSOMED HOLDING AG
7.20.1. INTRODUCTION
7.20.2. YPSOMED HOLDING AG PRODUCT PORTFOLIO
7.20.3. YPSOMED HOLDING AG RECENT ACTIVITIES
1.1. RESEARCH METHODS AND TOOLS
1.2. MARKET BREAKDOWN
1.2.1. BY SEGMENTS
1.2.2. BY GEOGRAPHY
1.2.3. BY STAKEHOLDERS
MARKET OVERVIEW AND INSIGHTS
2.1. DEFINITION
2.2. ANALYST INSIGHT & CURRENT MARKET TRENDS
2.2.1. KEY FINDINGS
2.2.2. RECOMMENDATION
2.2.3. CONCLUSION
2.3. REGULATIONS
2.3.1. UNITED STATES
2.3.2. EUROPEAN UNION
2.3.3. CHINA
2.3.4. INDIA
2.3.5. REST OF THE WORLD
2.4. PATENT ANALYSIS
MARKET DETERMINANT
3.1. MOTIVATORS
3.1.1. RISE IN PREVALENCE RATE OF DIABETES
3.1.2. INCREASE IN AWARENESS TOWARDS DIABETES AND INSULIN DELIVERY DEVICES
3.1.3. GOVERNMENT SUPPORT AND FAVOURABLE REIMBURSEMENT IN SOME ECONOMIES
3.1.4. ACCURACY AND EFFICIENCY OF INSULIN DELIVERY DEVICES
3.2. RESTRAINTS
3.2.1. RISK OF INFECTION WITH NEEDLES AND SYRINGES
3.2.2. LACK OF REIMBURSEMENT POLICIES IN SOME COUNTRIES
3.2.3. ORAL INSULIN EMERGING AS AN ALTERNATIVE OPTION
3.3. OPPORTUNITIES
3.3.1. TECHNOLOGICAL ADVANCEMENTS
3.3.2. GROWTH OF RESEARCH AND DELIVERY ACTIVITIES
3.3.3. INCREASE IN DIABETES RELATED SPENDING IN EMERGING ECONOMIES
MARKET SEGMENTATION
4.1. INSULIN DELIVERY DEVICES MARKET BY TYPE
4.1.1. INSULIN SYRINGES
4.1.2. INSULIN PENS
4.1.3. INSULIN JET INJECTORS
4.1.4. EXTERNAL INSULIN PUMPS
4.1.5. OTHERS
4.2. INSULIN DELIVERY DEVICES MARKET BY DISTRIBUTION CHANNELS
4.2.1. HOSPITALS PHARMACY
4.2.2. ONLINE SALES
4.2.3. DIABETES CENTRES
4.2.4. RETAIL PHARMACY
4.3. INSULIN DELIVERY DEVICES MARKET BY END-USER INDUSTRY
4.3.1. HOSPITALS & CLINICS
4.3.2. HOMECARE USAGE
COMPETITIVE LANDSCAPE
5.1. KEY STRATEGIES
5.2. KEY COMPANY ANALYSIS
REGIONAL ANALYSIS
6.1. NORTH AMERICA
6.1.1. UNITED STATES
6.1.2. CANADA
6.1.3. REST OF NORTH AMERICA
6.2. EUROPE
6.2.1. UNITED KINGDOM
6.2.2. FRANCE
6.2.3. GERMANY
6.2.4. ITALY
6.2.5. SPAIN
6.2.6. REST OF EUROPE
6.3. ASIA PACIFIC
6.3.1. INDIA
6.3.2. CHINA
6.3.3. JAPAN
6.4. REST OF THE WORLD
COMPANY PROFILES
7.1. ABBOTT LABORATORIES
7.1.1. INTRODUCTION
7.1.2. ABBOTT LABORATORIES PRODUCT PORTFOLIO
7.1.3. ABBOTT LABORATORIES RECENT ACTIVITIES
7.2. ANIMAS CORPORATION
7.2.1. INTRODUCTION
7.2.2. ANIMAS CORPORATION PRODUCT PORTFOLIO
7.2.3. ANIMAS CORPORATION RECENT ACTIVITIES
7.3. ASTRAZENECA PLC
7.3.1. INTRODUCTION
7.3.2. ASTRAZENECA PLC PRODUCT PORTFOLIO
7.3.3. ASTRAZENECA PLC RECENT ACTIVITIES
7.4. B. BRAUN MESELGEN AG
7.4.1. INTRODUCTION
7.4.2. B. BRAUN MESELGEN AG PRODUCT PORTFOLIO
7.4.3. B. BRAUN MESELGEN AG RECENT ACTIVITIES
7.5. BECTON, DICKINSON AND COMPANY
7.5.1. INTRODUCTION
7.5.2. BECTON, DICKINSON AND COMPANY PRODUCT PORTFOLIO
7.5.3. BECTON, DICKINSON AND COMPANY RECENT ACTIVITIES
7.6. BIOCON LIMITED
7.6.1. INTRODUCTION
7.6.2. BIOCON LIMITED PRODUCT PORTFOLIO
7.6.3. BIOCON LIMITED RECENT ACTIVITIES
7.7. BRISTOL-MYERS SQUIBB
7.7.1. INTRODUCTION
7.7.2. BRISTOL-MYERS SQUIBB PRODUCT PORTFOLIO
7.7.3. BRISTOL-MYERS SQUIBB RECENT ACTIVITIES
7.8. ELI LILLY AND COMPANY
7.8.1. INTRODUCTION
7.8.2. ELI LILLY AND COMPANY PRODUCT PORTFOLIO
7.8.3. ELI LILLY AND COMPANY RECENT ACTIVITIES
7.9. F. HOFFMANN-LA ROCHE, LTD.
7.9.1. INTRODUCTION
7.9.2. F. HOFFMANN-LA ROCHE, LTD. PRODUCT PORTFOLIO
7.9.3. F. HOFFMANN-LA ROCHE, LTD. RECENT ACTIVITIES
7.10. INSULET CORPORATION
7.10.1. INTRODUCTION
7.10.2. INSULET CORPORATION PRODUCT PORTFOLIO
7.10.3. INSULET CORPORATION RECENT ACTIVITIES
7.11. JULPHAR
7.11.1. INTRODUCTION
7.11.2. JULPHAR PRODUCT PORTFOLIO
7.11.3. JULPHAR RECENT ACTIVITIES
7.12. MANNKIND CORPORATION
7.12.1. INTRODUCTION
7.12.2. MANNKIND CORPORATION PRODUCT PORTFOLIO
7.12.3. MANNKIND CORPORATION RECENT ACTIVITIES
7.13. MEDTRONIC PLC
7.13.1. INTRODUCTION
7.13.2. MEDTRONIC PLC PRODUCT PORTFOLIO
7.13.3. MEDTRONIC PLC RECENT ACTIVITIES
7.14. NOVO NORDISK A/S
7.14.1. INTRODUCTION
7.14.2. NOVO NORDISK A/S PRODUCT PORTFOLIO
7.14.3. NOVO NORDISK A/S RECENT ACTIVITIES
7.15. PFIZER INC.
7.15.1. INTRODUCTION
7.15.2. PFIZER INC. PRODUCT PORTFOLIO
7.15.3. PFIZER INC. A/S RECENT ACTIVITIES
7.16. SANOFI
7.16.1. INTRODUCTION
7.16.2. SANOFI PRODUCT PORTFOLIO
7.16.3. SANOFI RECENT ACTIVITIES
7.17. SCIGEN
7.17.1. INTRODUCTION
7.17.2. SCIGEN PRODUCT PORTFOLIO
7.17.3. SCIGEN RECENT ACTIVITIES
7.18. TANDEM DIABETES CARE, INC.
7.18.1. INTRODUCTION
7.18.2. TANDEM DIABETES CARE, INC. PRODUCT PORTFOLIO
7.18.3. TANDEM DIABETES CARE, INC. RECENT ACTIVITIES
7.19. WOCKHARDT LTD.
7.19.1. INTRODUCTION
7.19.2. WOCKHARDT LTD. PRODUCT PORTFOLIO
7.19.3. WOCKHARDT LTD. RECENT ACTIVITIES
7.20. YPSOMED HOLDING AG
7.20.1. INTRODUCTION
7.20.2. YPSOMED HOLDING AG PRODUCT PORTFOLIO
7.20.3. YPSOMED HOLDING AG RECENT ACTIVITIES
LIST OF TABLES
Table 1 GLOBAL INSULIN DELIVERY DEVICES MARKET RESEARCH AND ANALYSIS BY TYPE, 2015-2022 ($ MILLION)
Table 2 GLOBAL INSULIN SYRINGES MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
Table 3 GLOBAL INSULIN PENS MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
Table 4 GLOBAL INSULIN JET INJECTORS MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
Table 5 GLOBAL EXTERNAL INSULIN PUMPS MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
Table 6 GLOBAL OTHERS MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
Table 7 GLOBAL INSULIN DELIVERY DEVICES MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNELS, 2015-2022 ($ MILLION)
Table 8 GLOBAL HOSPITALS PHARMACY MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
Table 9 GLOBAL ONLINE SALES MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
Table 10 GLOBAL DIABETES CENTRES MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
Table 11 GLOBAL RETAIL PHARMACY MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
Table 12 GLOBAL INSULIN DELIVERY DEVICES MARKET BY END USER INDUSTRY
Table 13 GLOBAL HOSPITALS & CLINICS MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
Table 14 GLOBAL HOMECARE USAGE MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
Table 15 ABBOTT LABORATORIES PRODUCT PORTFOLIO
Table 16 ABBOTT LABORATORIES RECENT ACTIVITIES
Table 17 ANIMAS CORPOTATION PRODUCT PORTFOLIO
Table 18 ANIMAS CORPOTATION RECENT ACTIVITIES
Table 19 ASTRAZENECA PLC PRODUCT PORTFOLIO
Table 20 ASTRAZENECA PLC RECENT ACTIVITIES
Table 21 B. BRAUN MESELGEN AG PRODUCT PORTFOLIO
Table 22 B. BRAUN MESELGEN AG RECENT ACTIVITIES
Table 23 BECTON, DICKINSON AND COMPANY PRODUCT PORTFOLIO
Table 24 BECTON, DICKINSON AND COMPANY RECENT ACTIVITIES
Table 25 BIOCON LIMITED PRODUCT PORTFOLIO
Table 26 BIOCON LIMITED RECENT ACTIVITIES
Table 27 BRISTOL-MYERS SQUIBB PRODUCT PORTFOLIO
Table 28 BRISTOL-MYERS SQUIBB RECENT ACTIVITIES
Table 29 ELI LILLY AND COMPANY PRODUCT PORTFOLIO
Table 30 ELI LILLY AND COMPANY RECENT ACTIVITIES
Table 31 F. HOFFMANN-LA ROCHE, LTD. PRODUCT PORTFOLIO
Table 32 F. HOFFMANN-LA ROCHE, LTD. RECENT ACTIVITIES
Table 33 INSULET CORPORATION PRODUCT PORTFOLIO
Table 34 INSULET CORPORATION RECENT ACTIVITIES
Table 35 JULPHAR PRODUCT PORTFOLIO
Table 36 JULPHAR RECENT ACTIVITIES
Table 37 MANNKIND CORPORATION PRODUCT PORTFOLIO
Table 38 MANNKIND CORPORATION RECENT ACTIVITIES
Table 39 MEDTRONIC PLC PRODUCT PORTFOLIO
Table 40 MEDTRONIC PLC RECENT ACTIVITIES
Table 41 NOVO NORDISK A/S PRODUCT PORTFOLIO
Table 42 NOVO NORDISK A/S RECENT ACTIVITIES
Table 43 PFIZER INC. PRODUCT PORTFOLIO
Table 44 PFIZER INC. A/S RECENT ACTIVITIES
Table 45 SANOFIPRODUCT PORTFOLIO
Table 46 SANOFI RECENT ACTIVITIES
Table 47 SCIGEN PRODUCT PORTFOLIO
Table 48 SCIGENRECENT ACTIVITIES
Table 49 TANDEM DIABETES CARE, INC.PRODUCT PORTFOLIO
Table 50 TANDEM DIABETES CARE, INC. RECENT ACTIVITIES
Table 51 WOCKHARDT LTD. PRODUCT PORTFOLIO
Table 52 WOCKHARDT LTD. RECENT ACTIVITIES
Table 53 YPSOMED HOLDING AG PRODUCT PORTFOLIO
Table 54 YPSOMED HOLDING AG RECENT ACTIVITIES
Table 1 GLOBAL INSULIN DELIVERY DEVICES MARKET RESEARCH AND ANALYSIS BY TYPE, 2015-2022 ($ MILLION)
Table 2 GLOBAL INSULIN SYRINGES MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
Table 3 GLOBAL INSULIN PENS MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
Table 4 GLOBAL INSULIN JET INJECTORS MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
Table 5 GLOBAL EXTERNAL INSULIN PUMPS MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
Table 6 GLOBAL OTHERS MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
Table 7 GLOBAL INSULIN DELIVERY DEVICES MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNELS, 2015-2022 ($ MILLION)
Table 8 GLOBAL HOSPITALS PHARMACY MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
Table 9 GLOBAL ONLINE SALES MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
Table 10 GLOBAL DIABETES CENTRES MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
Table 11 GLOBAL RETAIL PHARMACY MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
Table 12 GLOBAL INSULIN DELIVERY DEVICES MARKET BY END USER INDUSTRY
Table 13 GLOBAL HOSPITALS & CLINICS MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
Table 14 GLOBAL HOMECARE USAGE MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
Table 15 ABBOTT LABORATORIES PRODUCT PORTFOLIO
Table 16 ABBOTT LABORATORIES RECENT ACTIVITIES
Table 17 ANIMAS CORPOTATION PRODUCT PORTFOLIO
Table 18 ANIMAS CORPOTATION RECENT ACTIVITIES
Table 19 ASTRAZENECA PLC PRODUCT PORTFOLIO
Table 20 ASTRAZENECA PLC RECENT ACTIVITIES
Table 21 B. BRAUN MESELGEN AG PRODUCT PORTFOLIO
Table 22 B. BRAUN MESELGEN AG RECENT ACTIVITIES
Table 23 BECTON, DICKINSON AND COMPANY PRODUCT PORTFOLIO
Table 24 BECTON, DICKINSON AND COMPANY RECENT ACTIVITIES
Table 25 BIOCON LIMITED PRODUCT PORTFOLIO
Table 26 BIOCON LIMITED RECENT ACTIVITIES
Table 27 BRISTOL-MYERS SQUIBB PRODUCT PORTFOLIO
Table 28 BRISTOL-MYERS SQUIBB RECENT ACTIVITIES
Table 29 ELI LILLY AND COMPANY PRODUCT PORTFOLIO
Table 30 ELI LILLY AND COMPANY RECENT ACTIVITIES
Table 31 F. HOFFMANN-LA ROCHE, LTD. PRODUCT PORTFOLIO
Table 32 F. HOFFMANN-LA ROCHE, LTD. RECENT ACTIVITIES
Table 33 INSULET CORPORATION PRODUCT PORTFOLIO
Table 34 INSULET CORPORATION RECENT ACTIVITIES
Table 35 JULPHAR PRODUCT PORTFOLIO
Table 36 JULPHAR RECENT ACTIVITIES
Table 37 MANNKIND CORPORATION PRODUCT PORTFOLIO
Table 38 MANNKIND CORPORATION RECENT ACTIVITIES
Table 39 MEDTRONIC PLC PRODUCT PORTFOLIO
Table 40 MEDTRONIC PLC RECENT ACTIVITIES
Table 41 NOVO NORDISK A/S PRODUCT PORTFOLIO
Table 42 NOVO NORDISK A/S RECENT ACTIVITIES
Table 43 PFIZER INC. PRODUCT PORTFOLIO
Table 44 PFIZER INC. A/S RECENT ACTIVITIES
Table 45 SANOFIPRODUCT PORTFOLIO
Table 46 SANOFI RECENT ACTIVITIES
Table 47 SCIGEN PRODUCT PORTFOLIO
Table 48 SCIGENRECENT ACTIVITIES
Table 49 TANDEM DIABETES CARE, INC.PRODUCT PORTFOLIO
Table 50 TANDEM DIABETES CARE, INC. RECENT ACTIVITIES
Table 51 WOCKHARDT LTD. PRODUCT PORTFOLIO
Table 52 WOCKHARDT LTD. RECENT ACTIVITIES
Table 53 YPSOMED HOLDING AG PRODUCT PORTFOLIO
Table 54 YPSOMED HOLDING AG RECENT ACTIVITIES
LIST OF FIGURES
Figure 1 NORTH AMERICA MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
Figure 2 US MARKET RESEARCH AND ANALYSIS, 2015-2022($ MILLION)
Figure 3 CANADA MARKET RESEARCH AND ANALYSIS, 2015-2022($ MILLION)
Figure 4 EUROPEAN MARKET RESEARCH AND ANALYSIS, 2015-2022($ MILLION)
Figure 5 UK MARKET RESEARCH AND ANALYSIS, 2015-2022($ MILLION)
Figure 6 FRANCE MARKET RESEARCH AND ANALYSIS, 2015-2022($ MILLION)
Figure 7 GERMANY MARKET RESEARCH AND ANALYSIS, 2015-2022($ MILLION)
Figure 8 ITALY MARKET RESEARCH AND ANALYSIS, 2015-2022($ MILLION)
Figure 9 SPAIN MARKET RESEARCH AND ANALYSIS, 2015-2022($ MILLION)
Figure 10 ROE MARKET RESEARCH AND ANALYSIS, 2015-2022($ MILLION)
Figure 11 ASIA PACIFIC MARKET RESEARCH AND ANALYSIS, 2015-2022($ MILLION)
Figure 12 INDIA MARKET RESEARCH AND ANALYSIS, 2015-2022($ MILLION)
Figure 13 CHINA MARKET RESEARCH AND ANALYSIS, 2015-2022($ MILLION)
Figure 14 JAPAN MARKET RESEARCH AND ANALYSIS, 2015-2022($ MILLION)
Figure 15 ROPAC MARKET RESEARCH AND ANALYSIS, 2015-2022($ MILLION)
Figure 16 REST OF THE WORLD MARKET RESEARCH AND ANALYSIS, 2015-2022($ MILLION)
Figure 1 NORTH AMERICA MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
Figure 2 US MARKET RESEARCH AND ANALYSIS, 2015-2022($ MILLION)
Figure 3 CANADA MARKET RESEARCH AND ANALYSIS, 2015-2022($ MILLION)
Figure 4 EUROPEAN MARKET RESEARCH AND ANALYSIS, 2015-2022($ MILLION)
Figure 5 UK MARKET RESEARCH AND ANALYSIS, 2015-2022($ MILLION)
Figure 6 FRANCE MARKET RESEARCH AND ANALYSIS, 2015-2022($ MILLION)
Figure 7 GERMANY MARKET RESEARCH AND ANALYSIS, 2015-2022($ MILLION)
Figure 8 ITALY MARKET RESEARCH AND ANALYSIS, 2015-2022($ MILLION)
Figure 9 SPAIN MARKET RESEARCH AND ANALYSIS, 2015-2022($ MILLION)
Figure 10 ROE MARKET RESEARCH AND ANALYSIS, 2015-2022($ MILLION)
Figure 11 ASIA PACIFIC MARKET RESEARCH AND ANALYSIS, 2015-2022($ MILLION)
Figure 12 INDIA MARKET RESEARCH AND ANALYSIS, 2015-2022($ MILLION)
Figure 13 CHINA MARKET RESEARCH AND ANALYSIS, 2015-2022($ MILLION)
Figure 14 JAPAN MARKET RESEARCH AND ANALYSIS, 2015-2022($ MILLION)
Figure 15 ROPAC MARKET RESEARCH AND ANALYSIS, 2015-2022($ MILLION)
Figure 16 REST OF THE WORLD MARKET RESEARCH AND ANALYSIS, 2015-2022($ MILLION)
